Literature DB >> 24798744

Splenic marginal-zone lymphoma: ontogeny and genetics.

Panagiotis Baliakas1, Jonathan C Strefford, Vasilis Bikos, Marina Parry, Kostas Stamatopoulos, David Oscier.   

Abstract

Splenic marginal-zone lymphoma (SMZL) is a rare tumor that has recently emerged as a prototype for how the interplay between genetics and environment shapes the natural history of lymphomas. Indeed, the recent identification of molecular immunogenetic subgroups within SMZL may prove to be relevant not only for the sub-classification of the disease but also for improved understanding of the underlying biology. In contrast to other B-cell lymphomas, SMZL lacks a characteristic genetic lesion, although the majority of cases harbor genomic aberrations, as recently revealed by high-throughput studies that identified recurrent genetic aberrations, several in pathways related to marginal-zone differentiation and B-cell signaling. Here we provide an overview of recent research into the molecular and cellular biology of SMZL and related disorders, with special emphasis on immunogenetics and genomic aberrations, and discuss the value of molecular and cellular markers for the diagnosis and differential diagnosis of these entities.

Entities:  

Keywords:  Lymphoma and Hodgkin disease; cytogenetics; molecular genetics

Mesh:

Year:  2014        PMID: 24798744     DOI: 10.3109/10428194.2014.919636

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN: 1026-8022


  6 in total

1.  Toll-like receptor stimulation in splenic marginal zone lymphoma can modulate cell signaling, activation and proliferation.

Authors:  Eleonora Fonte; Andreas Agathangelidis; Daniele Reverberi; Stavroula Ntoufa; Lydia Scarfò; Pamela Ranghetti; Giovanna Cutrona; Alessandra Tedeschi; Aliki Xochelli; Federico Caligaris-Cappio; Maurilio Ponzoni; Chrysoula Belessi; Zadie Davis; Miguel A Piris; David Oscier; Paolo Ghia; Kostas Stamatopoulos; Marta Muzio
Journal:  Haematologica       Date:  2015-08-20       Impact factor: 9.941

Review 2.  Improved biological insight and influence on management in indolent lymphoma. Talk 3: update on nodal and splenic marginal zone lymphoma.

Authors:  Catherine Thieblemont
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2017-12-08

Review 3.  Murine Models of Splenic Marginal Zone Lymphoma: A Role for Cav1?

Authors:  Chelsey L Patten; Christine E Cutucache
Journal:  Front Oncol       Date:  2016-12-14       Impact factor: 6.244

Review 4.  Deciphering splenic marginal zone lymphoma pathogenesis: the proposed role of microRNA.

Authors:  Jacob E Robinson; Christine E Cutucache
Journal:  Oncotarget       Date:  2018-07-06

5.  Homeobox NKX2-3 promotes marginal-zone lymphomagenesis by activating B-cell receptor signalling and shaping lymphocyte dynamics.

Authors:  Eloy F Robles; Maria Mena-Varas; Laura Barrio; Sara V Merino-Cortes; Péter Balogh; Ming-Qing Du; Takashi Akasaka; Anton Parker; Sergio Roa; Carlos Panizo; Idoia Martin-Guerrero; Reiner Siebert; Victor Segura; Xabier Agirre; Laura Macri-Pellizeri; Beatriz Aldaz; Amaia Vilas-Zornoza; Shaowei Zhang; Sarah Moody; Maria Jose Calasanz; Thomas Tousseyn; Cyril Broccardo; Pierre Brousset; Elena Campos-Sanchez; Cesar Cobaleda; Isidro Sanchez-Garcia; Jose Luis Fernandez-Luna; Ricardo Garcia-Muñoz; Esther Pena; Beatriz Bellosillo; Antonio Salar; Maria Joao Baptista; Jesús Maria Hernandez-Rivas; Marcos Gonzalez; Maria Jose Terol; Joan Climent; Antonio Ferrandez; Xavier Sagaert; Ari M Melnick; Felipe Prosper; David G Oscier; Yolanda R Carrasco; Martin J S Dyer; Jose A Martinez-Climent
Journal:  Nat Commun       Date:  2016-06-14       Impact factor: 14.919

Review 6.  CD5-Negative, CD10-Negative Low-Grade B-Cell Lymphoproliferative Disorders of the Spleen.

Authors:  John J Schmieg; Jeannie M Muir; Nadine S Aguilera; Aaron Auerbach
Journal:  Curr Oncol       Date:  2021-12-04       Impact factor: 3.677

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.